BEHANDLUNG VON HYPERBILIRUBINÄMIE

European patent · EP3851537 · In force

Register entry

Publication number
EP3851537
Application number
EP21151019
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 27, 2015
Published
Jul 21, 2021
Granted
Dec 27, 2023
Protection ends at the latest
Apr 26, 2035
Next annual fee due
Apr 30, 2027
IPC classes
C12N 15/86 (2006.01)
A61K 48/00 (2006.01)
C12N 9/10 (2006.01)
A61K 38/45 (2006.01)
A61P 1/16 (2006.01)
Priority
EP 14305622 25.04.2014
EP 14196400 04.12.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. Nov 6, 2024

    Change

    Published in Swissreg on 06.11.2024

  4. May 23, 2024

    Change

    Published in Swissreg on 23.05.2024

  5. Dec 27, 2023

    Granted

    Published in Swissreg on 27.12.2023

Parties

Holder

Genethon

1 bis rue de l'Internationale, 91000 Evry, FR

International Centre for Genetic Engineering and Biotechnology

International Centre For Genetic Engineering And Biotechnology

AREA Science Park Padriciano 99, 34149 Trieste, IT

Inventor

COLLAUD, Fanny

75019 Paris, FR

RONZITTI, Giuseppe

77300 Fontainebleau, FR

MURO, Andrés

34128 Trieste, IT

MINGOZZI, Federico

Philadelphia, Pennsylvania 19118, US

BORTOLUSSI, Giulia

33090 Travesio, IT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.